According to MBS’ press release, the BBI Group, partner to the world’s leading diagnostic and healthcare organisations, has entered into a definitive agreement to acquire the Maine Biotechnology Services, Inc. (MBS) located in Portland, Maine (USA). The acquisition of MBS will expand BBI’s portfolio during a period of expansion and growth. The company provides a range of products to the diagnostic, healthcare, research food sectors globally. MBS will add antibody development to its capability and product range. Read full story
BBI Group Acquires Maine Biotechnology Services
Related Posts
UMaine professor McGill receives top German research award
ORONO — University of Maine ecology professor Brian McGill was awarded the Humboldt Research Award, one of the most prestigious scientific...
Four Maine workforce programs could get $6.5M in fed funding
Four workforce training programs in Maine could receive nearly $6.5 million in federal funding through the markup of the fiscal year 2024 financial...
Music as medicine: FDA approves stroke damage therapy from Portland startup
Doctors may soon start writing an unconventional prescription to help stroke survivors regain their ability to walk: music. MedRhythms, a Portland...